Observational Study With InnoLet® in Daily Clinical Practice

Novo Nordisk A/S1,030 enrolled

Overview

This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.

Study Type

OBSERVATIONAL

Enrollment

1,030

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin humanDRUG

Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes mellitus (Type 1 or type 2) * Need insulin treatment

Locations (1)

Novo Nordisk Investigational Site

Seoul, South Korea

Outcomes

Primary Outcomes

Change in HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Adverse events: Serious and non-serious

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.